Literature DB >> 23182133

Malaria sporozoite challenge model comes of age.

José A Stoute1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23182133      PMCID： PMC4005127          DOI： 10.1179/2047772412Z.00000000080

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN： 2047-7724            Impact factor:   2.894


× No keyword cloud information.
  6 in total

1.  Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers.

Authors:  Meta Roestenberg; Sake J de Vlas; An-Emmie Nieman; Robert W Sauerwein; Cornelus C Hermsen
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

2.  Addressing the bottleneck at clinical testing of candidate malaria vaccines.

Authors:  Denise L Doolan; Simon H Apte
Journal:  Pathog Glob Health       Date:  2012-10       Impact factor: 2.894

3.  A field trial to assess a blood-stage malaria vaccine.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Matthew B Laurens; Amed Ouattara; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Idrissa Traore; Bourema Kouriba; Dapa A Diallo; Issa Diarra; Modibo Daou; Amagana Dolo; Youssouf Tolo; Mahamadou S Sissoko; Amadou Niangaly; Mady Sissoko; Shannon Takala-Harrison; Kirsten E Lyke; Yukun Wu; William C Blackwelder; Olivier Godeaux; Johan Vekemans; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; Darby Thompson; Tina Dube; Lorraine Soisson; Carter L Diggs; Brent House; David E Lanar; Sheetij Dutta; D Gray Heppner; Christopher V Plowe
Journal:  N Engl J Med       Date:  2011-09-15       Impact factor: 91.245

4.  Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge.

Authors:  L W Church; T P Le; J P Bryan; D M Gordon; R Edelman; L Fries; J R Davis; D A Herrington; D F Clyde; M J Shmuklarsky; I Schneider; T W McGovern; J D Chulay; W R Ballou; S L Hoffman
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

5.  Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum.

Authors:  J D Chulay; I Schneider; T M Cosgriff; S L Hoffman; W R Ballou; I A Quakyi; R Carter; J H Trosper; W T Hockmeyer
Journal:  Am J Trop Med Hyg       Date:  1986-01       Impact factor: 2.345

6.  Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

Authors:  Michele D Spring; James F Cummings; Christian F Ockenhouse; Sheetij Dutta; Randall Reidler; Evelina Angov; Elke Bergmann-Leitner; V Ann Stewart; Stacey Bittner; Laure Juompan; Mark G Kortepeter; Robin Nielsen; Urszula Krzych; Ev Tierney; Lisa A Ware; Megan Dowler; Cornelus C Hermsen; Robert W Sauerwein; Sake J de Vlas; Opokua Ofori-Anyinam; David E Lanar; Jack L Williams; Kent E Kester; Kathryn Tucker; Meng Shi; Elissa Malkin; Carole Long; Carter L Diggs; Lorraine Soisson; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; D Gray Heppner
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240
  6 in total
  2 in total

1.  Addressing the bottleneck at clinical testing of candidate malaria vaccines.

Authors:  Denise L Doolan; Simon H Apte
Journal:  Pathog Glob Health       Date:  2012-10       Impact factor: 2.894

2.  Plasmodium vivax sporozoite challenge in malaria-naïve and semi-immune Colombian volunteers.

Authors:  Myriam Arévalo-Herrera; David A Forero-Peña; Kelly Rubiano; José Gómez-Hincapie; Nora L Martínez; Mary Lopez-Perez; Angélica Castellanos; Nora Céspedes; Ricardo Palacios; José Millán Oñate; Sócrates Herrera
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.